HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cardiac overexpression of constitutively active Galpha q causes angiotensin II type1 receptor activation, leading to progressive heart failure and ventricular arrhythmias in transgenic mice.

AbstractBACKGROUND:
Transgenic mice with transient cardiac expression of constitutively active Galpha q (Gαq-TG) exhibt progressive heart failure and ventricular arrhythmias after the initiating stimulus of transfected constitutively active Gαq becomes undetectable. However, the mechanisms are still unknown. We examined the effects of chronic administration of olmesartan on heart failure and ventricular arrhythmia in Gαq-TG mice.
METHODOLOGY/PRINCIPAL FINDINGS:
Olmesartan (1 mg/kg/day) or vehicle was chronically administered to Gαq-TG from 6 to 32 weeks of age, and all experiments were performed in mice at the age of 32 weeks. Chronic olmesartan administration prevented the severe reduction of left ventricular fractional shortening, and inhibited ventricular interstitial fibrosis and ventricular myocyte hypertrophy in Gαq-TG. Electrocardiogram demonstrated that premature ventricular contraction (PVC) was frequently (more than 20 beats/min) observed in 9 of 10 vehicle-treated Gαq-TG but in none of 10 olmesartan-treated Gαq-TG. The collected QT interval and monophasic action potential duration in the left ventricle were significantly shorter in olmesartan-treated Gαq-TG than in vehicle-treated Gαq-TG. CTGF, collagen type 1, ANP, BNP, and β-MHC gene expression was increased and olmesartan significantly decreased the expression of these genes in Gαq-TG mouse ventricles. The expression of canonical transient receptor potential (TRPC) 3 and 6 channel and angiotensin converting enzyme (ACE) proteins but not angiotensin II type 1 (AT1) receptor was increased in Gαq-TG ventricles compared with NTG mouse ventricles. Olmesartan significantly decreased TRPC6 and tended to decrease ACE expressions in Gαq-TG. Moreover, it increased AT1 receptor in Gαq-TG.
CONCLUSIONS/SIGNIFICANCE:
These findings suggest that angiotensin II type 1 receptor activation plays an important role in the development of heart failure and ventricular arrhythmia in Gαq-TG mouse model of heart failure.
AuthorsNaoko Matsushita, Toshihide Kashihara, Hisashi Shimojo, Satoshi Suzuki, Tsutomu Nakada, Yasuchika Takeishi, Ulrike Mende, Eiichi Taira, Mitsuhiko Yamada, Atsushi Sanbe, Masamichi Hirose
JournalPloS one (PLoS One) Vol. 9 Issue 8 Pg. e106354 ( 2014) ISSN: 1932-6203 [Electronic] United States
PMID25171374 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adaptor Proteins, Signal Transducing
  • Agtrap protein, mouse
  • Collagen Type I
  • Imidazoles
  • Myh7 protein, mouse
  • Tetrazoles
  • Atrial Natriuretic Factor
  • olmesartan
  • Myosin Heavy Chains
  • GTP-Binding Protein alpha Subunits, Gq-G11
Topics
  • Adaptor Proteins, Signal Transducing (genetics, metabolism)
  • Animals
  • Atrial Natriuretic Factor (metabolism)
  • Collagen Type I (metabolism)
  • Disease Models, Animal
  • GTP-Binding Protein alpha Subunits, Gq-G11 (genetics)
  • Gene Expression Regulation (drug effects)
  • Heart Failure (genetics, physiopathology, prevention & control)
  • Imidazoles (administration & dosage)
  • Mice
  • Mice, Transgenic
  • Myosin Heavy Chains (metabolism)
  • Tetrazoles (administration & dosage)
  • Ventricular Premature Complexes (genetics, physiopathology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: